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ABSTRACT 
Most newborn screening laboratories use CE-marked or FDA-approved test-kits, like in routine clinical chemistry. Na-
tional regulations require only minimal evaluation from the customer, if the test-kits are used as specified by the manu-
facturer. The microtiter-based kit-concept is often based on the perception, that the laboratory always processes whole 
microtiter plates. However, in the daily routine, this is rather a rare exception, which leads to much higher costs per 
newborn, compared to the costs per assay in the test-kits. In addition, the amount of wasted resources is quite high. Per-
formance of the Neonatal Total Galactose kit from Perkin Elmer was tested. We have determined specificity, limit of 
detection (LOD), limit of quantitation (LOQ), intra and inter assay variation, recovery, stability of measuring signal and 
reagents. Results were also compared with the Astoria Pacific Spot Check System. In addition, we had (by chance) the 
opportunity to test 2 kits, which were already expired for more than 3 years. LOD was 165 - 306 µmol/L and LOQ 475 
- 703 µmol/L, depending on the definition of LOD/LOQ. Mean recovery was 112.8%, intra assay CVs were 11.3, 7.3, 
4.0, and 3.0, and inter assay CVs 28.7, 15.9, 7.8, and 9.3, at 220, 590, 1200, and 2060 µmol/L respectively. Reconsti-
tuted and mixed reagents must be used within some hours, and were unstable even if stored at −20˚C. However, if the 
reconstituted galactose substrate reagent and galactose oxidase reagent were only mixed according to the daily require-
ments, and the rest stored separately at −20˚C, they were stable for at least 12 days. The performance of the expired 
test-kits did not differ from the others. The performance of the Total Galactose kit is comparable to other tests used for 
newborn screening. However, we could significantly reduce the costs per newborn and reduce unnecessary production 
of waste, by thorough validation and modification of the assay procedures.  
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1. Introduction 
Newborn Screening for Galactosemia was introduced in 
the 1970s [1]. While the classical “Beutler-Test” can only 
detect newborns with classical galactosaemie [2], the 
determination of total galactose [3,4] will also detect 
newborns with galactokinase deficiency and uridine di-
phosphate galactose-4-epimerase deficiency.   
Most newborn screening laboratories use CE-marked 
or FDA-approved test-kits, like in routine clinical chem- 
istry. National regulations require only minimal evalua- 
tion from the customer if the test-kits are used as speci- 
fied by the manufacturer. The microtiter-based kit-con- 
cept is often based on the perception, that the laboratory  
always processes whole microtiter plates. However, in 
the daily routine of newborn screening laboratories, this 
is rather a rare exception, which leads to much higher 
costs per newborn, compared to the costs per assay in the 
test-kits. In addition, the amount of wasted resources is 
quite high. We have thoroughly tested the performance 
of the Neonatal Total Galactose kit from Perkin Elmer. 
We have determined specificity, LOD, LOQ, intra- and 
inter-assay variation, recovery, signal stability of the flu-
orescent reaction product, and stability of reagents. Re-
sults were also compared with the Astoria Pacific Spot 
Check System. In addition, we had (by chance) the op-
portunity to test 2 kits, which were already expired for 
more than 3 years. 
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2. Materials and Methods 
Total Galactose was determined from whole blood, dried 
on filterpaper, with the Neonatal Total Galactose test-kit 
from Perkin Elmer. For the determination of intra and inter 
assay variation various kit controls were used (concen- 
trations up to 726 µmol/L). In addition, dried blood sam- 
ples with galactose concentrations above 1000 µmol/L 
were prepared by adding galactose to whole blood of a 
healthy adult volunteer. After thorough mixing, the blood 
was spotted onto filterpaper and let dry for several hours. 
Control samples were stored at −18˚C. The Galactose- 
Oxidase/Substrate-Reagent has to be mixed from recon-
stituted Galactose-Oxidase-Reagent and Galactose-Sub- 
strate-Reagent. One vial of lyophilized Galactose-Oxi- 
dase-Reagent has to be dissolved with 6 mL of recon- 
stitution buffer and one vial of Galactose-Substrate-Re- 
agent has to be dissolved with 2 mL of reconstitution 
buffer. This results in 8 mL of Galactose-Oxidase/Sub- 
strate-Reagent which is sufficient for one microtiterplate. 
Reconstituted and mixed reagents must be used within 
one hour, and were unstable even if stored at −20˚C. Due 
to the instability of reconstituted Galactose-Oxidase/ 
Substrate-Reagent, we used a modified assay procedure. 
After reconstitution of Galactose-Oxidase-Reagent and 
Galactose-Substrate-Reagent only the necessary amount 
of Galactose-Oxidase/Substrate-Reagent is mixed. A 
whole vial of Galactose-Oxidase-Reagent and Galac- 
tose-Substrate-Reagent for a whole microtiterplate, and x 
* 750 µL of reconstituted Galactose-Oxidase-Reagent 
and x * 375 µL of reconstituted Galactose-Substrate- 
Reagent. With x being the number of rows on the micro- 
titerplate that contain samples. Then all mixed Galactose- 
Oxidase/Substrate-Reagent is pooled for the whole daily 
batch. With this procedure one calibration curve on the 
first plate is sufficient for the daily batch, in contrast to the  
kit instructions, which call for a calibration curve on each 
plate. Residual reagents can be stored at −20˚C, and will 
be used the next working day.  
The performance of the PE-kit for routine newborn 
screening was compared with the results of the Astoria 
Pacific Spot Check Kit. 
3. Results 
When the Total Galactose Kit was used according to our 
modified assay procedure, reagents are stable for at least 
12 days (Figure 1). The fluorescent signal of the reaction 
product, after stopping the reaction, was stable for more 
than 3 hours (Figure 2). 
Values for LOD, LOQ are shown in Table 1, and val- 
ues for intra- and inter-assay-variation are shown in Ta- 
ble 2, at various concentration levels. Mean recovery was 
112.8%. The correct determination of LOD and LOQ is 
difficult. Whole blood samples without endogenous ga- 
lactose are hard to obtain and the measurement of plain 
white filterpaper gives significantly higher values than 
kit-calibrator A (n = 30, p < 0.001). This is also reflected 
by the very high values of the statistically achieved 
LOD4, LOQ1, and LOQ2. 
Our data show, that the use of the unweighted linear 
regression algorithm, as proposed by the manufacturer, 
results in an underestimation of the galactose concentra-
tions above 1000 µmol/L (Figure 3). The use of a spline 
function for calibration curves gives much more reliable 
results. 
Comparison of the Total Galactose kit from PE with the 
Astoria Pacific Spot Check Kit under routine conditions 
showed no perfect correlation. The best curve fit was 
achieved with a quadric equation (Figure 4). 
The performance of the test-kits, that were expired for 
more than 3 years, showed no difference to still valid test  
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Figure 1. Stability of reagents stored at −20˚C according to our modified assay procedure. 
Copyright © 2013 SciRes.                                                                               JASMI 
Determination of Total Galactose from Dried Blood Spots—Extensive Assay Evaluation of a CE-Marked Test-Kit 165
 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
sample no.
G
al
 [µ
m
ol
/L
]
0 min
5 min
10 min
15 min
20 min
25 min
30 min
35 min
40 min
45 min
50 min
55 min
60 min
65 min
70 min
75 min
80 min
85 min
90 min
105 min
120 min
135 min
150 min
165 min
190 min  
Figure 2. Signal stability of the fluorescent reaction product. After adding stop solution and shaking, 35 samples with galactose 
concentrations between 50 - 3600 µmol/L were repeatedly measured up to 190 min. 
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Figure 3. Comparison of measured and predicted galactose concentrations, up 5556 µmol/L. Galactose concentrations were 
calculated with the proposed linear regression algorithm. 
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Figure 4. Comparison of the Total Galactose test-kit from PE with the Astoria Spot Check kit under routine conditions. 3650 
newborn samples (), 20 CDC quality control samples (), and 2 samples from a newborn with classical galacto-saemia (). 
Linear regression (••••), and calculated quadric correlation (—). 
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Table 1. Limit of detection and limit of quantitation of the Total Galactose assay. 
 Values from kit-inserts Values determined 
Analyte LOB1 LOD2 LOQ3 Linearity LOD4 LOQ1 LOQ2 LOQ3 
Total Galactose [µmol/L] 39 72 No information 72 - 3108 306 476 703 <83 
LOB1 = limit of blanc; defined as the 95th centile of a distribution of blank samples. LOD2 = limit of detection; according to NCCLS document EP17-A. LOQ3 
= limit of quantitation; defined as the lowest concentration with a total CV equal to or less than 20%. LOD4 = limit of detection; defined as the mean of a sam-
ple without analyte + 3 SD (blanc filterpaper). LOQ1 = limit of quantitation; defined as the mean of a sample without analyte + 6 SD (blanc filterpaper). LOQ2 
= limit of quantitation; defined as the mean of a sample without analyte + 10 SD (blanc filterpaper). LOQ3 = limit of quantitation; defined as the lowest concen-
tration with a total CV equal to or less than 20%. 
 
Table 2. Intra- and inter-assay variation at various galactose concentrations. 
 Intraassay variation (n = 10) Interassay variation (n = 30) 
Galactose [μmol/L] 226 357 457 592 726* 1215 1509 2059 177 283 479 604 1397 2262
c.v. [%] 11.3 7.9 7.4 7.1 11.6 4.0 4.8 3.0 25.7 10.3 15.9 7.3 8.3 9.3
*Determination of total galactose with the PE-kit is not influenced by EDTA up to 100 mM. Mean value of 18 control samples with EDTA concentrations from 
0 - 100 mM: 719 µmol/L, c.v. 9.8%. 
 
kits (data not shown). 
4. Discussion 
Newborn screening laboratories have to measure all 
screening samples on the day of arrival in the laboratory. 
Therefore it is extremely rare that the total sample number 
of a daily routine, including calibrators and controls, will 
exactly (or nearly) fill a whole microtiterplate, or two, 
three, etc. But since the reagents in the Total Galactose kit 
from Perkin Elmer are packed for one plate, respectively, 
sticking to the procedures outlined in the kit-insert will 
result in a significant waste of reagents, and hence in-
crease of costs per newborn. This can be up to 50% sub-
ject to the number of samples per day. In addition, the 
stated expiry date seems to be unnecessarily short, which 
could also lead to unnecessary waste of reagents in small 
screening laboratories. 
Our data show that a thorough in house validation 
even of CE-marked test-kits can significantly improve 
the overall performance of a test, including economical 
aspects. 
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